Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets

Citation
Olerud, Johan, Magnus Johansson, Jack Lawler, Nils Welsh, and Per-Ola Carlsson. 2008. Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes 57(7): 1870-1877.

Published Version
doi://10.2337/db07-0724

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:8097016

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets

Johan Olerud, Magnus Johansson, Jack Lawler, Nils Welsh, and Per-Ola Carlsson

OBJECTIVE—Insufficient development of a new intra-islet capillary network after transplantation may be one contributing factor to the failure of islet grafts in clinical transplantation. The present study tested the hypothesis that the angiostatic factor thrombospondin-1 (TSP-1), which is normally present in islets, restricts intra-islet vascular expansion posttransplantation.

RESEARCH DESIGN AND METHODS—Pancreatic islets of TSP-1–deficient (TSP-1−/−) mice or wild-type islets transfected with siRNA for TSP-1 were transplanted beneath the renal capsule of syngeneic or immunocompromised recipient mice.

RESULTS—Both genetically TSP-1−/− islets and TSP-1 siRNA-transfected islet cells demonstrated an increased vascular density when compared with control islets 1 month after transplantation. This was also reflected in a markedly increased blood perfusion and oxygenation of the grafts. The functional importance of the improved vascular engraftment was analyzed by comparing glucose-stimulated insulin release from islet cells transfected with either TSP-1 siRNA or scramble siRNA before implantation. These experiments showed that the increased revascularization of grafts composed of TSP-1 siRNA-transfected islet cells correlated to increments in both their first and second phase of glucose-stimulated insulin secretion.

CONCLUSIONS—Our findings demonstrate that inhibition of TSP-1 in islets intended for transplantation may be a feasible strategy to improve islet graft revascularization and function. Diabetes 57:1870–1877, 2008

Despite improvements in immunosuppression protocols over the last years, pancreatic islets from at least two donor pancreata are still needed to reverse type 1 diabetes in clinical islet transplantation (1,2). This is far more than the alleged 10–20% of the total islet volume suggested to be enough to maintain normoglycemia in humans. Moreover, in contrast to the results for whole-organ transplantation, there seems to be a continuous decline in islet graft function, and very few patients remain insulin-independent at 5 years posttransplantation (2,3). Because the histocompatibility barrier, the underlying autoimmune disease, and the immunosuppressive agents used are the same for both transplantation procedures, it is likely that issues related to the adaptation of the implanted islets to their new microenvironment play a role for the differences in results.

Pancreatic islets become disconnected from their vascular supply during collagenase digestion before transplantation. Revascularization of transplanted islets has been shown to be concluded within 7–14 days (4). However, the resulting vascular density remains lower than in endogenous islets (5–7) and is associated with an impaired oxygenation (6,8) and endocrine function (7,9,10).

We have recently observed that freshly isolated rodent islets become better revascularized and function better than islets cultured for several days before transplantation (11), although the islet vascular system, also when using freshly isolated islets for transplantation, is far from fully restored. One possible explanation for the improved vascular engraftment in such islets is that not only host blood vessels but also remnant donor islet endothelial cells may participate in the formation of a new islet vascular network (12–14). However, despite the presence of several mitogens for endothelial cells within the islets, such as vascular endothelial growth factor (VEGF), fibroblast growth factor, and matrix metalloproteinases (15–17), intra-islet endothelial cells normally have a very low proliferation rate (18,19). This endothelial quiescence is presumably due to the fact that pro-angiogenic factors normally are counteracted by anti-angiogenic factors present in the islets (20), including the islet endothelial cells themselves (21,22). A possible key factor in this context is thrombospondin-1 (TSP-1), because it is not downregulated by hypoxia (20), which occurs posttransplantation. Moreover, animals deficient of this glycoprotein are characterized by hypervascular islets (23). The present study tested the hypothesis that use of genetically TSP-1−/− islets or transfection of islets in vitro with siRNA for TSP-1 would create a microenvironment permissive for blood vessel growth within islets and improve vascular engraftment and function after transplantation.

RESEARCH DESIGN AND METHODS
Pancreatic islets from wild-type (TSP-1+/−), heterozygous TSP-1+/−, and TSP-1−/− C57BL/6 mice of the F2-F3 generations were used for transplantation. The TSP-1−/− mice were generated by homologous recombination in 129/Sv-derived ES cells implanted in C57BL/6 blastocysts (24). A breeding program of such mice was established at Uppsala University, and male mice 10–12 weeks of age were allocated to the studies. Age-matched wild-type male C57BL/6 mice were used as controls. Recipient C57BL/6 (nu/nu) mice weighing ~30 g were purchased from M&B Research and Breeding Center (Ry, Denmark). For experiments with siRNA, adult, inbred C57BL/6 mice (M&B) were used both as islet donors and recipients. All animals had free access to...
water and food throughout the course of the study. The experiments were approved by the animal ethics committee for Uppsala University.

Islet isolation and culture. Islets from wild-type, TSP-1−/−, and TSP-1−/− C57BL/6 mice were prepared by collagenase digestion (25) and cultured at 37°C free-floating in 5 ml culture medium composed of RPMI 1640 (Sigma-Aldrich, Irvine, U.K.), to which we added 11 mmol/l glucose, 10% (vol/vol) FCS (Sigma-Aldrich), 0.17 mmol/l sodium benzoicillin, and 0.17 mmol/l streptomycin.

**PCR primers and siRNA sequences**

| Gene/siRNA | GenBank accession number | Primer/siRNA sequence (5′–3′) |
|------------|--------------------------|-------------------------------|
| β-Actin*   | NM_007393 F | GCTCTGGCTCTCAGGACCC |
|            | NM_011580 F | GAGACCAGAAGACACAGCTG |
| TSP-1*     | NM_011580 F | GAGACCAGAAGACACAGCTG |
| Scramble siRNA† | CAAGUGAAGGAGAAAGACAGC |
| TSP-1 siRNA 1‡ | GAUAAGCAGGCAGCACAGCU |
| TSP-1 siRNA 2‡ | GCCUGAAGAAGACGCUU |
| TSP-1 siRNA 3‡ | CAAAGGCUCAGCCAU |
| TSP-1 siRNA 4‡ | CAUAGCCGAACAGAGCUU |

*Primers ordered from MWG Biotech (Ebersberg, Germany).
†Scramble siRNA sequence ordered from Dharmacon Research (Chicago).
‡TSP-1 siRNA sequences ordered from Qiagen (Hilden, Germany).
F: forward, R: reverse.

**Islet transplantation.** Grafts of 250 wild-type, TSP-1−/−, or TSP-1−/− C57BL/6 islets cultured for 3–4 days or re-aggregated scramble or TSP-1 siRNA transfected C57BL/6 islet cells were packed in a brassing pipette and syngeneically implanted beneath the capsule of the left kidney in nondiabetic C57BL/6 nu/nu mice anesthetized with avertin (2.5% [vol/vol] solution of 10 g 97% [vol/vol] 2,2,2-trihalomethanol) (Sigma-Aldrich) in 10 ml 2-methylbutanol) (Kemla, Stockholm, Sweden). For the transplanted material, all aggregated islet cells, irrespective of the size of the organoids, were transplanted.

**Measurements of blood flow and oxygen tension in transplanted islets.** One month posttransplantation, the animals were anesthetized with avertin (compare with above), placed on a heated operating table (38°C), and tracheotomized. Polyethylene catheters were inserted into the right carotid artery and left jugular vein. The latter catheter was connected to a Statham P234B pressure transducer (Statham Laboratories, Los Angeles, CA) to monitor arterial blood pressure, whereas the latter catheter was used for continuous infusion of Ringer solution (5 ml · kg−1 · h−1) to substitute for loss of body fluid.

After a left subcostal flank incision, the graft-bearing kidney was immobilized in a plastic cup. The kidney was embedded in cotton soaked in Ringer solution and covered with mineral oil (Apoteket, Gothenburg, Sweden) to prevent evaporation and keep the tissue moist at body temperature. The blood perfusion of the islet graft and the adjacent renal cortex was measured by laser-Doppler flowmetry (PF 4001-2; Perimed, Stockholm, Sweden). The laser-Doppler probe (outer tip diameter 0.45 mm) was positioned perpendicular to the immobilized tissue surface by the use of a micromanipulator, and care was taken not to cause any compression of the tissue. At least three blood flow measurements were performed in the transplanted islets and renal cortex in each animal. The mean of these measurements from each animal was calculated and considered to be one experiment. Because it is difficult to calibrate the instrument in physical units of blood flow, all blood flow values are given as arbitrary tissue perfusion units (TPU).

Oxygen tension was measured in the islet graft and the adjacent renal parenchyma with a oxygraph (Oxygraph; Ugo-Basile, Italy) described in detail previously (27,28). The electrodes (outer tip diameter 2–6 μm) were inserted into the tissues by the use of a micromanipulator under a stereomicroscope. At least 10 measurements were performed in both the islet graft and the renal cortex. The mean of all measurements, in each tissue and animal, was calculated and considered to be one experiment. During the blood flow and oxygen tension measurements, blood pressure, body temperature, and tissue temperature were continuously monitored with a MacLab Instrument (AD Instruments, Hastings, U.K.). A mean arterial blood pressure <75 mmHg was used as a preset exclusion criteria from the study.

**Measurements of blood parameters.** Blood glucose concentrations were determined with test reagent strips (Medisense; Baxter Travenol, Deerfield, IL) from samples obtained from the cut tip of the tail. At the end of blood flow and oxygen tension measurements, a blood sample was collected for analysis of hematocrit and blood gases. Animals with pH <7.30, PO2 <10 kPa, PCO2 >6.8 kPa, or hematocrit <40 were excluded from the study.

**Light microscopic evaluation.** The graft-bearing kidneys were removed after the oxygen tension and blood flow measurements, fixed in 10% (vol/vol) formaldehyde, and embedded in paraffin. Consecutive sections (5 μm thick) of the islet grafts were prepared and stained with the lectin Bandeiraea simplicifolia (BS-1) or a monoclonal guinea pig anti-insulin antibody (ICN Biomedicals), as previously described (5), and counterstained with hematoxylin. In each case, ~10 tissue sections stained with BS-1 or for insulin from all parts of the islet transplants were randomly chosen and evaluated. The blood vessel density and β-cell percentage in pancreatic islets was determined by a direct point-counting method (29). For this purpose, a grid with 121 intersections was placed onto each tissue section under a light microscope (BS-1, ×200; 19). The number of intersections among endothelial cells (stained with BS-1) or insulin-positive cells was then counted by an examiner unaware of the origin of the samples.

**Evaluation of islet graft function.** Grafts from some of the animals transplanted with scramble or TSP-1 siRNA-transfected wild-type islet

---

**TABLE 1**

| GenBank accession number | Primer/siRNA sequence (5′–3′) |
|--------------------------|-------------------------------|
| β-Actin* | NM_007393 F | GCTCTGGCTCTCAGGACCC |
| | NM_011580 F | GAGACCAGAAGACACAGCTG |
| TSP-1* | NM_011580 F | GAGACCAGAAGACACAGCTG |
| Scramble siRNA† | CAAGUGAAGGAGAAAGACAGC |
| TSP-1 siRNA 1‡ | GAUAAGCAGGCAGCACAGCU |
| TSP-1 siRNA 2‡ | GCCUGAAGAAGACGCUU |
| TSP-1 siRNA 3‡ | CAAAGGCUCAGCCAU |
| TSP-1 siRNA 4‡ | CAUAGCCGAACAGAGCUU |

*Primers ordered from MWG Biotech (Ebersberg, Germany).
†Scramble siRNA sequence ordered from Dharmacon Research (Chicago).
‡TSP-1 siRNA sequences ordered from Qiagen (Hilden, Germany).
F: forward, R: reverse. (ICN Biomedicals, Aurora, OH); the buffer is hereafter referred to as KRBH buffer. The KRBH buffer contained 1.67 mmol/l n-glucose during the 1st h of incubation at 37°C (O2/C02 = 95:5). The medium was removed and replaced by 250 μl KRBH buffer supplemented with 16.7 mmol/l glucose and incubated for a 2nd h. The medium was again removed, and the islet cells were harvested and homogenized in 200 μl redistilled water. The aqueous homogenate was then used for DNA measurements by fluorophotometry (PicoGreen dsDNA Quantiﬁcation kit; Molecular Probes, Eugene, OR). A fraction of the homogenate was mixed with acid-ethanol (0.18 mol/l HCl in 95% [vol/vol] ethanol), from which insulin was extracted over night at 4°C. Insulin contents in incubation medium and homogenates were determined by ELISA (Mercodia, Uppsala, Sweden).

**Islet transplantation.** Groups of islet cells from 10 islets were transferred in triplicate to glass vials containing 250 μl Krebs-Ringer bicarbonate HEPES (KRBH) buffer supplemented with 10 μmol/l HEPES (Sigma-Aldrich) and 2 mg/ml BSA.
cells were investigated 1 month posttransplantation for glucose-stimulated insulin secretion as previously described (30). Briefly, the graft-bearing left kidney was removed together with a part of the aorta and inferior vena cava. The ureter and the renal vein were cut, while the aorta was cannulated and infused with a continuously gassed (O2:CO2 95:5) Krebs-Ringer bicarbonate buffer supplemented with 2.0% (wt/vol) each of BSA (fraction V; Miles Laboratories, Slough, U.K.) and dextran T70 (Pharmacia, Uppsala, Sweden). At different times during the perfusion, the medium contained either 2.8 or 16.7 mmol/l D-glucose. The medium was supplemented with 2.0% (wt/vol) each of BSA and dextran T70 (Pharmacia, Uppsala, Sweden). At different times during the perfusion, the medium was analyzed on days 1, 3, and 7 after the transfection and is expressed as the TSP-1–to–HSP60 protein ratio from filters shown in C. Islet cells were lysed and separated by SDS-PAGE followed by 30 min using 16.7 mmol/l glucose. The perfusions were concluded by a 15-min perfusion with medium containing 2.8 mmol/l glucose, which was followed by 30 min using 16.7 mmol/l glucose. A 1.0-ml sample was collected at 14, 15, 16, 17, 18, 19, 20, 22, 25, 30, 35, 40, 45, 50, 55, and 60 min. The insulin concentrations of the effluent samples were measured by ELISA (Mercodia). The rate of insulin secretion was calculated by multiplying the insulin concentration in the sample by the flow rate, giving values of insulin expressed as nanograms per minute. 

**RESULTS**

**Animal characteristics.** All recipient mice allocated to the study weighed ~30 g at transplantation and had increased 5–10% in body weight when investigated 1 month later. Both donors of islets, including the TSP-1−/− mice, and recipients were normoglycemic with nonfasting blood glucose concentrations of ~7 mmol/l. All animals allocated to blood flow and oxygen tension measurements had a mean arterial blood pressure of 90–100 mmHg. No animals had to be excluded based on the preset exclusion criteria for blood gases and hematocrit. However, two animals were excluded from studies of islet graft blood flow and oxygen tension because of hypotension (mean arterial blood pressure <75 mmHg) following perioperative bleeding.

**Expression of TSP-1 in different organs.** TSP-1 immunoactivity was observed as a double band. When compared with spleen, pancreatic islets and kidneys contained low amounts of the protein TSP-1 (Fig. IA).

**Expression of TSP-1 mRNA and protein in islet cells after siRNA transfection.** Dispersed islet cells transfected with TSP-1 siRNA showed an ~40% reduction in

![Figure 1](image_url)

**FIG. 1.** Dispersed islet cells transfected with scramble or TSP-1 siRNA. A: TSP-1 protein expression in C57BL/6 mice tissues. The top panel shows TSP-1 protein expression in spleen, kidney, and freshly isolated islets. The bottom panel shows the same filter stained with amido black for total protein loading. The figure is representative for four separate experiments. B: TSP-1 mRNA expression 24 h posttransfection. Values are means ± SE for 6–11 experiments in each group. Each experiment represents a paired comparison of scramble siRNA and TSP-1 siRNA transfection with islet cells isolated and pooled from two mice. Separate experiments with native expression of TSP-1 in freshly isolated whole islets are included as reference. *P = 0.03 for TSP-1 siRNA when compared with scramble siRNA transfection. C: Islet cells were lysed and separated by SDS-PAGE and blotted onto nitrocellulose. The figure shows TSP-1 and HSP60 (used as loading control) immunoreactivity on the same filter. D: The TSP-1–to–HSP60 protein ratio from filters shown in C was analyzed on days 1, 3, and 7 after the transfection and is expressed as the TSP-1–to–scramble siRNA ratio. *P = 0.02 when compared with scramble siRNA transfection from four separate experiments.
TSP-1 mRNA expression compared with dispersed islet cells transfected with scramble siRNA when evaluated 24 h posttransfection (Fig. 1B). At the protein expression level, the effects of TSP-1 siRNA transfection caused a delayed effect, with a 40% decrease first after 1 week (Fig. 1C and D).

**Effects of TSP-1 siRNA transfection on islet function.** There were no differences in insulin release at low glucose concentrations (50.2 ± 5.5 vs. 47.2 ± 6.7 ng · μg DNA⁻¹ · h⁻¹), in insulin release at high glucose concentrations (203.0 ± 18.8 vs. 187.2 ± 19.3 ng · μg DNA⁻¹ · h⁻¹), or in islet insulin content (8.2 ± 0.1 vs. 7.5 ± 0.3 ng/ng DNA) between islet cells transfected with scramble siRNA or TSP-1 siRNA 72 h before measurements.

**Blood flow.** One month posttransplantation, the blood perfusion of grafts composed of wild-type control islets or scramble siRNA-transfected islet cells were similar and 40–50% of that in the adjacent renal cortex (Fig. 2A and B). In comparison, grafts composed of islet tissue either genetically decreased or deficient in TSP-1 (Fig. 2A) or transfected with siRNA for TSP-1 (Fig. 2B) had a markedly higher blood perfusion when compared with their corresponding control.

**Oxygen tension.** The pO₂ levels in islet grafts composed of wild-type control islets (Fig. 3A) or in islet cells transfected with scramble siRNA before transplantation (Fig. 3B) were 7–8 mmHg 1 month posttransplantation. Improved oxygenization compared with this was observed in islet grafts composed of TSP-1⁺⁻ islets, TSP-1⁻⁻ islets, or islet cells transfected with TSP-1 siRNA before transplantation (Fig. 3A and B, respectively).

**Vascular density.** Both wild-type control islets (Fig. 4A and B) and scramble siRNA-transfected islet tissue (Fig. 4D and E) had a blood vessel density of 7% 1 month posttransplantation. By contrast, both TSP-1⁻⁻ islets (Fig. 4A and C) and islet tissue transfected with siRNA for TSP-1 (Fig. 4D and F) had an 40% increase in vascular density. Islet grafts composed of TSP-1⁺⁻ islets had a vascular density in-between wild-type islet grafts and TSP-1⁻⁻ islet grafts (Fig. 4A). The increase in blood vessels numbers seemed to occur both in the center and

---

**FIG. 2.** Blood flow in renal subcapsular islet grafts and adjacent renal cortex 1 month posttransplantation. A: The islet grafts were composed of 250 wild-type (■), TSP-1⁻⁻ (■), or TSP-1⁻⁻ (□) islets. *P ≤ 0.003 when compared with wild-type islets. #P = 0.03 when TSP-1⁻⁻ was compared with TSP-1⁺⁻. B: The islet grafts were composed of 250 scramble (■) or TSP-1 siRNA-transfected (□) islets. *P = 0.04 when compared with scramble siRNA transfected islets. Blood flow values are expressed as TPU. Values are means ± SE for six experiments in each group.

**FIG. 3.** Oxygen tension in renal subcapsular islet grafts and adjacent renal cortex 1 month posttransplantation. A: The islet grafts were composed of 250 wild-type (■), TSP-1⁻⁻ (■), or TSP-1⁻⁻ (□) islets. B: The islet grafts were composed of 250 scramble (■) or TSP-1 siRNA-transfected (□) islets. Values are means ± SE for six experiments in each group. *P ≤ 0.001 when compared with control islets (■) in both A and B. #P = 0.003 when TSP⁻⁻ was compared with TSP⁻⁻.
peripheral regions of the TSP-1−/− islets and TSP-1 siRNA-transfected islet tissue.

**Islet transplant cell composition.** There were similar percentages of β-cells in grafts composed of wild-type islets or TSP-1−/− islets (84.7 ± 1.3% [n = 4] vs. 86.2 ± 0.9% [n = 5], respectively). Likewise, there was no difference in β-cell percentage in the islet tissue composed of scramble siRNA-transfected and TSP-1 siRNA-transfected islet cells at 1 month follow-up (85.1 ± 0.5 vs. 86.9 ± 1.3%, respectively).

**Islet graft function.** Perfusion of islet graft–bearing kidneys 1 month posttransplantation showed that islet tissue transfected with siRNA for TSP-1 had an improved first and second peak of insulin release when compared with scramble siRNA-transfected islet cells (Fig. 5A–C). Total AUC for glucose-stimulated insulin release in the TSP-1 siRNA-transfected islet tissue was thus increased by ∼40% (Fig. 5D).

**DISCUSSION**

Adult pancreatic islets have a dense glomerular-like angioarchitecture that requires VEGF-signaling from the β-cells for its formation and maintenance (31–34). However, despite chronic exposure to VEGF, vascular expansion does not normally occur in islets after the 1st postnatal week (35). Likewise, although increased amounts of not only VEGF but also other pro-angiogenic factors such as hepatocyte growth factor are secreted from newly transplanted islets (16,36), new blood vessel formation within the islets also during these conditions is sparse (5–7). Instead, a rich vascular network is formed in the stroma around each single transplanted islet (5). This suggests the presence of matrix- or tissue-bound angiostatic factors within the implanted islets that prevent intra-islet vascular formation. Marked overexpression of VEGF in the donor tissue has previously been shown in experimental studies to overcome this and to improve islet graft revascularization and function (9,10). However, silencing some of the angiostatic factors may be an even simpler strategy.

In this study, we tested the hypothesis that unopposing the action of already-present pro-angiogenic factors through silencing TSP-1 in islets would improve islet graft revascularization and function. The glycoprotein TSP-1 binds to the extracellular matrix (37,38) and exerts its main effects through inducing apoptosis selectively in activated endothelial cells, i.e., those that are forming new blood vessels, but not quiescent endothelium (39). It also inhibits angiogenesis by blocking the mobilization of pro-angiogenic factors, such as matrix metalloproteinase-9 and VEGF, and by inhibiting their access to co-receptors on the endothelial cell surface (40).

We investigated the influence of TSP-1 on islet graft revascularization using two different models: by transplanting genetically TSP-1 deficient islets and by transplanting islet cells transfected with siRNA for TSP-1 in vitro before transplantation. The first model thereby provides a persistent partial (TSP-1−/−) or complete loss (TSP-1−/−) of TSP-1 expression in the islets, whereas the latter causes only a transient decrease in TSP-1 levels. Using both approaches, we observed a markedly improved vascular engraftment of the transplanted islets with improved intra-islet vascular density at 1 month follow-up. In both models, the newly formed blood vessels also seemed to be functional, because the improved vascular density was reflected in an increased blood perfusion and pO₂ in the islet grafts. Notably, the pO₂ increase was especially prominent in the TSP-1−/− mice, where TSP-1 expression is chronically deficient and of a greater magnitude than the
increase in blood vessel numbers. It is possible that this reflects higher blood perfusion in individual blood vessels and thereby better oxygen transport capacities of islet blood vessels in the absence of TSP-1, e.g., due to loss of the previously described counteracting effect of TSP-1 on nitric oxide–mediated vasodilation (41). Nitric oxide is the main mediator of high blood perfusion in endogenous and transplanted islets (42,43). It should be noted that an intra-islet vasodilation is not necessarily reflected in increased total graft blood flow, which is measured by laser-Doppler flowmetry, because total graft blood flow represents not only the nutritive blood flow to the endocrine cells but also blood flow in the vast number of stroma capillaries. In contrast, it could be expected that the blood flow in capillaries in the endocrine parts mainly contributes to the delivery of oxygen to the endocrine cells due to limitations of oxygen diffusion (44).

In our characterization of TSP-1−/− mice, we observed that these mice had fasting and nonfasting blood glucose levels that were normal and did not differ from those of wild-type animals. However, despite that TSP-1−/− mice have been described to have an increased islet mass (23), closer investigations revealed that these animals were slightly glucose intolerant and had a decreased islet function (45), which probably reflects the role of TSP-1 in transforming growth factor-β1 activation (23). Nevertheless, we hypothesized that a transient decrease in islet TSP-1 levels during the acute revascularization phase of transplanted islets may still be beneficial for long-term islet function, considering that such a decrease also can be seen physiologically during the islet vascular expansion of pregnant rats. In our protocol for TSP-1 siRNA transfection of islet cells using Lipofectamine as vector, there was a transient decrease in islet TSP-1 levels at the mRNA and protein levels of a similar magnitude as seen in islets during pregnancy, i.e., 40%. In rapidly dividing cells, the silencing effect of siRNA usually lasts for 1 week, but it lasts for up to 3–4 weeks in nondividing cells both in vitro and in vivo (46). Probably because of the low proliferation rate of adult endocrine cells, including β-cells, and turnover rate of the extracellular matrix binding of the TSP-1 protein, silencing of TSP-1 in these cells was not manifested until after 1 week at the protein level. A partial effect of TSP-1 siRNA may also be on the remnant donor islet endothelial cells, because these cells also contain TSP-1 (22). However, in this

**FIG. 5.** Functional studies with perfusions of renal subcapsular islet grafts 1 month posttransplantation. A: Insulin release in response to 16.7 mmol/l glucose (bar) from grafts composed of 250 scramble (○) or TSP-1 siRNA-transfected islets (●). B–D: AUC for the first phase (B) of glucose-stimulated insulin release (min 14–18; *P = 0.006 when compared with control), the second phase (C) of glucose-stimulated insulin release (min 19–50; *P = 0.041 when compared with control), and both the first and second phase (D) of insulin release (min 14–50; *P = 0.025 when compared with control). Values are means ± SE for six experiments with all groups.
case, the effect is probably much shorter because of cell division as part of angiogenesis.

When graft function was evaluated by perfusion of graft-bearing kidneys 1 month posttransplantation, islet cells exposed to siRNA for TSP-1 before transplantation performed better than control islet cells exposed to scramble siRNA. The chosen model to evaluate graft function also enabled us to separately evaluate the effects of improved vascular engraftment on the insulin release kinetics from transplanted islets. It is noteworthy that the peak of the first phase of glucose-stimulated insulin secretion was substantially higher in the better revascularized islet grafts, which is similar to what we have previously observed when improving blood perfusion, but not revascularization, by angiotensin II receptor inhibition (47). However, in contrast to when only the blood perfusion was improved, we observed in the present study also an augmented second phase of glucose-stimulated insulin secretion. This suggests that the present findings do not merely reflect a “wash-out” effect of insulin retained in the tissue even further.

We conclude that transient inhibition of TSP-1 early posttransplantation may be used to improve islet graft revascularization and function. Such a strategy, e.g., by development of pharmacological inhibitors, may be more feasible in the clinical setting than trying to increase the expression of pro-angiogenic factors in the transplanted tissue even further.

ACKNOWLEDGMENTS

This work was supported by grants from The Swedish Research Council (55X-15043), The Juvenile Diabetes Research Foundation, the European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation/Novo Nordisk Research Programme 2006, The Swedish Diabetes Association, The Swedish Juvenile Diabetes Fund, The Åker Foundation, and The Family Ernfrös Fund.

The skilled technical assistance of Astrid Nordin, Birgit Bodin, and Eva Törnelius is gratefully acknowledged.

REFERENCES

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:220–238, 2000
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069, 2005
3. Humar A, Kandaswamy R, Grander D, Gruesser RW, Gruesser AC, Sutherland DE: Decreased surgical risks of pancreas transplantation in the modern era. Ann Surg 231:260–275, 2000
4. Mengel MD, Jaeger S, Walter F, Seifert H, Hammersen F, Messmer K: Angiogenesis and hemodynamics of microvasculature of transplanted islets of Langerhans. Diabetes 38 (Suppl. 1):109–201, 1989
5. Mattsson G, Jansson L, Carlsson PO: Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 51:1362–1366, 2002
6. Carlsson PO, Palm F, Mattsson G: Low revascularization of experimentally transplanted human pancreatic islets. J Clin Endocrinol Metab 87:5418–5423, 2002
7. Contreras JL, Smyth CA, Eckstein C, Bilbao G, Thompson JA, Young CJ, Eckhoff DE: Peripheral mobilization of resident bone marrow-derived endothelial progenitor cells enhances pancreatic islet revascularization and engraftment after intraportal transplantation. Surgery 134:390–398, 2003
8. Carlsson PO, Palm F, Andersson A, Liss P: Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 50:489–495, 2001
9. Zhang N, Better A, Suriawinata J, Harbaran S, Altonmote J, Cong L, Zhang H, Song K, Moseck M, Bromberg J, Dong H: Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 53:963–970, 2004
10. Lai Y, Schneider A, Kudsuma A, Hauck-Schmalenberger J, Breier G, Brandhorst D, Brandhorst H, Iken M, Brendel MD, Bretzel RG, Linn T: Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. Transplantation 79:1530–1536, 2005
11. Olsson R, Carlsson PO: Better vascular engraftment and function in pancreatic islets transplanted without prior culture. Diabetologia 48:469–476, 2005
12. Linn T, Schneider K, Hammes HP, Preissner KT, Brandhorst H, Morgenstern E, Kiefer F, Bretzel RG: Angiogenic capacity of endothelial cells in islets of Langerhans. FASEB J 17:981–983, 2003
13. Brissova M, Fowler M, Wiebe P, Shostak A, Shiota M, Radhika A, Lin PC, Gannon M, Powers AC: Intrainslet endothelial cells contribute to revascularization of transplanted pancreatic islets. Diabetes 53:1318–1325, 2004
14. Nypidt D, Kohler M, Wahlstedt H, Berggren PO: Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes 54:2287–2293, 2005
15. Kuroda M, Oka T, Oka Y, Yamochi T, Ohtsubo K, Mori S, Watanabe T, Machinami R, Ohnishi S: Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 90:3196–3200, 1995
16. Vasir B, Reitz P, Xu G, Sharma A, Bonner-Weir S, Weir GC: Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-alpha, TGF-beta, bFGF and Vimentin) in cultured and transplanted rat islets. Diabetologia 43:763–772, 2000
17. Barro C, Zaoui P, Morel F, Benhamou PY: Matrix metalloproteinase expression in rat pancreatic islets. Pancera 17:378–382, 1998
18. Lou J, Triponexx F, Oberholzer J, Wang Y, Du B, Buhler L, Cretin N, Mentha G, Wollheim CB, Morel P: Expression of α-1 proteinase inhibitor in human islet microvascular endothelial cells. Diabetes 48:1773–1778, 1999
19. Johansson M, Mattsson G, Andersson A, Jansson L, Carlsson PO: Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats. Endocrinology 147:2315–2324, 2006
20. Tillmar L, Welsh N: In vitro cultured rat islets express genes that both prevent and promote angiogenesis. JOP 5:81–91, 2004
21. Mattsson G, Danielsson A, Kriz V, Carlsson PO, Jansson L: Endothelial cell-enforced and endogenous transplanted pancreatic islets: differences in the expression of angiogenic peptides and receptors. Pcrancreaticology 6:86–95, 2006
22. Cantaluppi V, Biancone L, Romanazzi GM, Figliolini F, Beltramo S, Ninniri MS, Galimi F, Romagnoli R, Franchello A, Salizzoni M, Perin PC, Ricordi C, Segoloni GP, Camussi G: Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 6:2601–2611, 2006
23. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Galimi F, Beltramo S, Ninniri MS, Galimi F, Romagnoli R, Franchello A, Salizzoni M, Perin PC, Ricordi C, Segoloni GP, Camussi G: Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant 6:2601–2611, 2006
24. Hagerkvist R, Mokhtari D, Myers JW, Tengholm A, Welsh N: siRNA transfection of isolated pancreatic islets. ISLET GRAFT REVASCULARIZATION AND FUNCTION
29. Weibel E. Practical methods for biological morphometry. In Stereological Methods. Weibel E, Ed. London, Academic Press, 1979, p. 243–263

30. Korsgren O, Jansson L, Andersson A: Effects of hyperglycemia on function of isolated mouse pancreatic islets transplanted under kidney capsule. Diabetes 38:540–545, 1989

31. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193–202, 2002

32. Brissossa M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, Chen Z, Carr C, Jerome WG, Chen J, Baldwin HS, Nicholson W, Bader DM, Jetton T, Gannon M, Powers AC: Pancreatic islet production of vascular endothelial growth factor-a is essential for islet vascularization, revascularization, and function. Diabetes 55:2974–2985, 2006

33. Lammert E, Gu G, McLaughlin M, Brown D, Brekken R, Murtaugh LC, Gerber HP, Ferrara N, Melton DA: Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 13:1070–1074, 2003

34. Vasir B, Jonas JC, Steil GM, Hollister-Lock J, Hasenkamp W, Sharma A, Bonner-Weir S, Weir GC: Gene expression of VEGF and its receptors Flk-1/KDR and Flt-1 in cultured and transplanted rat islets. Transplantation 71:924–935, 2001

35. Lawler J: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1–12, 2002

36. Armstrong LC, Bornstein P: Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63–71, 2003

37. Lawler J: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 98:12485–12490, 2001

38. Swenson AM, Olszewski CR, Jones S, Jansson L: Inhibition of nitric oxide synthase by NG-nitro-L-arginine causes a preferential decrease in pancreatic islet blood flow in normal rats and spontaneously diabetic GK rats. Endocrinology 135:849–853, 1994

39. Dionne KE, Colton CK, Yarmush ML: Effect of oxygen on isolated pancreatic tissue. ASAIO Trans 35:739–741, 1989

40. Olerud J, Johansson M, Johansson Å, Welsh N, Carlsson PO: Thrombospondin-1: produced by islet endothelial cells and crucial for beta-cell function. Diabet Med 23 (Suppl. 1):418A, 2006

41. Derek W, Bartlett, Davis ME: Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:12, 2006

42. Carlsson PO, Nordin A, Palm F: pH is decreased in transplanted rat pancreatic islets. Am J Physiol Endocrinol Metab 284:E499–E504, 2003

43. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fassler R, Gu G, Gerber HP, Ferrara N, Melton DA, Lammert E: The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation. Dev Cell 10:397–405, 2006

44. Carlsson PO, Nordin A, Palm F: pH is decreased in transplanted rat pancreatic islets. Am J Physiol Endocrinol Metab 284:E499–E504, 2003

45. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fassler R, Gu G, Gerber HP, Ferrara N, Melton DA, Lammert E: The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation. Dev Cell 10:397–405, 2006

46. Carlsson PO, Nordin A, Palm F: pH is decreased in transplanted rat pancreatic islets. Am J Physiol Endocrinol Metab 284:E499–E504, 2003

47. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fassler R, Gu G, Gerber HP, Ferrara N, Melton DA, Lammert E: The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation. Dev Cell 10:397–405, 2006

48. Carlsson PO, Nordin A, Palm F: pH is decreased in transplanted rat pancreatic islets. Am J Physiol Endocrinol Metab 284:E499–E504, 2003

49. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fassler R, Gu G, Gerber HP, Ferrara N, Melton DA, Lammert E: The vascular basement membrane: a niche for insulin gene expression and beta cell proliferation. Dev Cell 10:397–405, 2006

50. Johansson Å, Johansson M, Carlson PO: Islet endothelial cell signaling augment beta cell function. Diabetologia 49 (Suppl. 1):317A–318A, 2006